METHOD OF EVALUATION OF INHIBITOR POTENTIAL SPECIFIC AND SELECTIVE FOR A DEFINED MOLECULAR TARGET

The invention relates to a method of evaluation of the potential specific and selective for an oncogenic molecular target tyrosine kinase JAK2 V617F involved in pathogenesis of myeloproliferative neoplasms (MPN). According to the invention, the method consists of the following stages: preparing a se...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CONSTANTINESCU ŞTEFAN NICULAE, MATEI LILIA, ECONOMESCU CHIVU MIHAELA, BOTEZATU ANCA, IANCU IULIA VIRGINIA, PĂIŞ ALEXANDRA- CRISTIANA, MAMBET CRISTINA, GHEORGHE GINA, NECULA LAURA GEORGIANA, GURBAN PETRUŢA, IONESCU VLAD- ALEXANDRU, DIACONU CARMEN CRISTINA, GAMAN MIHNEA- ALEXANDRU, BLEOTU CORALIA, DRAGU LAURA- DENISA, PANĂ LAVINIA- MIHAELA, PITICA IOANA- MĂDĂLINA
Format: Patent
Sprache:eng ; rum
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to a method of evaluation of the potential specific and selective for an oncogenic molecular target tyrosine kinase JAK2 V617F involved in pathogenesis of myeloproliferative neoplasms (MPN). According to the invention, the method consists of the following stages: preparing a set of cell lines which express, in a stable way, JAK2 V617F, the physiological homologue JAK2 WT and the mutant homologue JAK2 V658F, respectively, determining the anti-proliferative effect of the compounds with inhibitor potential tested by monitoring in real time the cellular modifications with IncuCyte system, the cytotoxicity by determining the ATP production by luminometrical analysis using CTG Luminiscence test, analyzing the mode of inducing anti-proliferative effect (apoptosis or necrosis) and the effect on the cellular cycle, by flow cytometry, for the purpose of identifying inhibitors with high specificity and selectivity for JAK2 V617F target. Invenţia se referă la o metodă de evaluare a potenţialului specific şi selectiv pentru o ţintă moleculară tirozinkinaza oncogenică JAK2 V617F implicată în patogeneza neoplasmelor mieloproliferative (NMP). Metoda, conform invenţiei, constă în etapele: obţinerea unui set de linii celulare care exprimă stabil JAK2 V617F, respectiv, omologul fiziologic JAK2 WT şi omologul mutant JAK1 V658F, determinarea efectului anti-proliferativ al compuşilor cu potenţial inhibitor testaţi prin monitorizarea in timp real a modificărilor celulare cu sistemul IncuCyte, citotoxicitatea prin determinarea producţiei de ATP prin analiza luminometrică cu testul CTG Luminiscence, analiza modului de inducere a efectului anti-proliferativ (apoptoză sau necroză) şi efectul asupra ciclului celular, prin citometrie în flux, în scopul identificării unor inhibitori cu specificitate înaltă şi selectivitae pentru ţinta JAK2 V617F.